Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorders.

March 7, 2025 – The FDA has approved a new gene therapy for macular telangiectasia type 2 (MacTel), a rare eye disease that causes vision loss. The approval marks the first and only ...

But all that has changed for him and a group of other children following a revolutionary new gene therapy breakthrough. Researchers from London's Moorfields Eye Hospital, biotech firm MeiraGTx and ...

Treatment shows potential to slow the progression of human degenerative eye diseases, including retinitis pigmentosa.

Get Instant Summarized Text (Gist) Tiny changes in the timing of expression of the gene orthodenticle (otd) can significantly affect eye size in fruit flies. In Drosophila mauritiana, earlier ...